While the clinical activity of sitravatinib in antiangiogenic agent-refractory RCC observed in our study appears promising in light of these data, particularly considering that most patients in METEOR had received only one prior VEGFR TKI, direct cross-study comparison is not recommended due to variances in design, including lack of a comparator arm in our study, and study populations. This evidence concerns the gene KDR and renal cell carcinoma.